Announcement

Lineage Reports Progress on Cell Therapy Aimed at Restoring Auditory Nerve Function

Lineage Cell Therapeutics announced that its experimental ReSonance program completed the preclinical development activities planned for the first year of its research collaboration with William Demant Invest and will advance into a second year. ReSonance is being investigated as a way to treat hearing loss by transplanting replacement auditory nerve cells into the cochlea.

The program takes a different approach from hearing aids, cochlear implants, and gene therapies. Rather than amplifying sound or targeting a specific genetic mutation, it aims to address damage to the auditory neurons themselves, the nerve cells that carry sound signals from the inner ear to the brain. The company says the therapy targets a subgroup of people with severe-to-profound sensorineural hearing loss, particularly some cochlear implant recipients whose limited benefit may be linked to auditory nerve degeneration. Alongside the update, collaborators at the Eriksholm Research Center published a review paper in the journal Hearing Research on how to identify candidates for this kind of therapy and how cells might be delivered surgically to the cochlea.

This is early-stage preclinical research. ReSonance is not an approved treatment, no human trials have begun, and the company has scheduled a meeting with a regulatory agency to discuss development plans. Any path to clinical use would require years of further research. 

Learn more here.